The Board of Directors of the Company at its meeting held on August 01, 2025, has, inter alia, considered and approved the Unaudited Financial Results of the Company (Standalone andConsolidated), for the quarter ended June 30, 2025
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
HCG announced its Q1 FY26 (quarter ended June 30, 2025) unaudited results, approved by the Board on August 1, 2025, with an unqualified limited review report from BSR & Co. LLP. On a consolidated basis, revenue from operations grew ~16.6% YoY to Rs. 61,180 lakhs (vs Rs. 52,469 lakhs in Q1 FY25), but profit for the period fell ~56% to Rs. 598 lakhs (vs Rs. 1,363 lakhs). Standalone revenue rose ~3.9% to Rs. 32,593 lakhs, while standalone PAT declined ~74% to Rs. 334 lakhs, weighed down by higher employee costs, finance costs, depreciation, and an exceptional loss of Rs. 155 lakhs. Q1 FY25 numbers were restated to give effect to a common-control business transfer (Nagpur oncology hospital). Notable corporate actions: KKR affiliate (Hector Asia Holdings II) acquired 51.59% promoter stake on May 30, 2025 at Rs. 445/share, an open offer for an additional 26% at Rs. 504.41/share is underway, and the company paid Rs. 5,808 lakhs in cash to settle surrendered ESOPs.
Sharp YoY fall in profitability (PAT down 56-74%) despite decent topline growth signals margin pressure and higher operating costs, which is a negative for near-term sentiment. However, the change of control to KKR (a large global PE sponsor), the open offer at a premium, and the ESOP cash settlement mark a transformational event that could bring strategic capital, governance changes, and longer-term value creation for shareholders.